Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RVMD

Revolution Medicines Inc

Jul 26 • 04:00PM ET

46.44

Dollar change +0.88
Percentage change 1.93	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI VB XBI VBK VXF IBB IWO SCHA IWN

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.76	Insider Own	16.80%	Shs Outstand	164.67M	Perf Week	0.65%
Market Cap	7.66B	Forward P/E	-	EPS next Y	-3.75	Insider Trans	-0.65%	Shs Float	137.27M	Perf Month	20.87%
Income	-484.27M	PEG	-	EPS next Q	-0.77	Inst Own	82.65%	Short Float	11.48%	Perf Quarter	31.45%
Sales	4.57M	P/S	1676.62	EPS this Y	15.95%	Inst Trans	7.96%	Short Ratio	10.26	Perf Half Y	66.04%
Book/sh	10.46	P/B	4.44	EPS next Y	-15.46%	ROA	-32.48%	Short Interest	15.76M	Perf Year	83.48%
Cash/sh	10.33	P/C	4.50	EPS next 5Y	-	ROE	-36.17%	52W Range	15.44 - 48.61	Perf YTD	61.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-36.05%	ROI	-26.82%	52W High	-4.46%	Beta	1.41
Dividend TTM	-	Quick Ratio	18.45	Sales past 5Y	11.11%	Gross Margin	-108.91%	52W Low	200.78%	ATR (14)	1.85
Dividend Ex-Date	-	Current Ratio	18.45	EPS Y/Y TTM	-23.63%	Oper. Margin	-12108.78%	RSI (14)	63.65	Volatility	3.38% 4.55%
Employees	378	Debt/Eq	0.05	Sales Y/Y TTM	-86.89%	Profit Margin	-10606.04%	Recom	1.19	Target Price	59.50
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	1.94%	Payout	-	Rel Volume	0.72	Prev Close	45.56
Sales Surprise	-100.00%	EPS Surprise	6.20%	Sales Q/Q	-100.00%	Earnings	May 08 AMC	Avg Volume	1.54M	Price	46.44
SMA20	7.93%	SMA50	14.49%	SMA200	46.63%	Trades		Volume	1,099,305	Change	1.93%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-16-24	Reiterated	Needham	Buy	$46 → $62
Jul-12-24	Initiated	Barclays	Overweight	$52
Jul-08-24	Initiated	Jefferies	Buy	$63
Apr-12-24	Reiterated	Needham	Buy	$36 → $46
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy	$36 → $48
Mar-11-24	Initiated	Piper Sandler	Overweight	$43
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy	$31 → $34
Jan-04-24	Initiated	Wedbush	Outperform	$41
Nov-16-23	Initiated	Raymond James	Outperform	$30
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight	$32 → $38
Dec-14-22	Initiated	Needham	Buy	$31
Oct-21-22	Initiated	Oppenheimer	Outperform	$30
May-20-22	Initiated	BofA Securities	Neutral	$24
Mar-01-22	Upgrade	Stifel	Hold → Buy	$36 → $26
Sep-23-21	Initiated	Stifel	Hold	$34
Aug-12-21	Downgrade	Goldman	Buy → Neutral	$49 → $27
May-18-21	Initiated	Goldman	Buy	$49
May-21-20	Initiated	H.C. Wainwright	Buy	$55
Mar-09-20	Initiated	JP Morgan	Neutral	$32
Mar-09-20	Initiated	Guggenheim	Buy	$50

Show Previous Ratings

Jul-11-24 12:00PM	Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer (GlobeNewswire)
Jul-10-24 05:58AM	Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last? (Zacks)
Jul-08-24 04:05PM	Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024 (GlobeNewswire) +5.46% +10.97%
Jun-08-24 09:00AM	The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024 (InvestorPlace)
Jun-05-24 04:05PM	Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
06:00AM	Loading…
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-09-24 03:41PM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 09:58PM	RVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024 (InvestorPlace)
04:02PM	Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-01-24 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024 (GlobeNewswire)
Apr-09-24 03:34PM	Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-08-24 11:36AM	Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-04-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-28-24 04:05PM	Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Feb-26-24 05:20PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-20-24 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024 (GlobeNewswire)
Feb-01-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-17-24 09:55AM	Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High? (Zacks)
Jan-04-24 07:00AM	Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-09-23 09:10AM	Revolution Medicines Completes Acquisition of EQRx (GlobeNewswire) -5.48%
Nov-08-23 11:30AM	Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition (GlobeNewswire)
Nov-07-23 10:14AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:55PM	Revolution Medicines Inc (RVMD) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
04:05PM	Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-01-23 07:00AM	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote FOR Proposed Acquisition of EQRx, Inc. (GlobeNewswire)
Oct-31-23 04:15PM	Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023 (GlobeNewswire) +7.90%
Oct-23-23 04:06PM	Revolution Crashes 34% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining. (Investor's Business Daily) -34.38% +14.52%
01:48PM	Rebel's Edge - October 20: $TGH, $RVMD, and Astros VS Rangers (TheStreet.com)
12:04PM	Loading…
12:04PM	Why Revolution Medicines Stock Is Crashing Today (Motley Fool)
10:07AM	Revolution Medicines Crashes 39% On Lackluster Test Results In Cancer Treatment (Investor's Business Daily)
Oct-22-23 02:30AM	Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 (GlobeNewswire)
Oct-19-23 07:02AM	Insider Sell: COO Margaret Horn Sells 25,000 Shares of Revolution Medicines Inc (GuruFocus.com)
Oct-16-23 03:19PM	Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90 (Investor's Business Daily) +14.08%
09:45AM	Revolution Medicines, Inc. (RVMD) Soars 23.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-13-23 02:54PM	Why Shares of Revolution Medicines Were Popping on Friday (Motley Fool) +23.60%
11:50AM	Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting (GlobeNewswire)
Oct-04-23 04:05PM	Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast (GlobeNewswire)
Sep-20-23 07:01AM	Insider Sell: COO Margaret Horn Sells 7,514 Shares of Revolution Medicines Inc (RVMD) (GuruFocus.com)
Sep-19-23 07:00AM	Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor (GlobeNewswire)
Aug-17-23 04:05PM	Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins (GlobeNewswire)
Aug-09-23 02:13PM	Industry Analysts Just Made A Sizeable Upgrade To Their Revolution Medicines, Inc. (NASDAQ:RVMD) Revenue Forecasts (Simply Wall St.)
Aug-08-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Aug-03-23 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023 (GlobeNewswire)
Aug-01-23 02:34PM	EQRx sells to another Alexis Borisy biotech after multiple pivots (American City Business Journals) +20.00%
07:00AM	Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital (GlobeNewswire)
Jul-06-23 09:59AM	Revolution Medicines Insider Ups Holding During Year (Simply Wall St.)
Jun-09-23 08:29AM	We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate (Simply Wall St.)
Jun-08-23 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.69%
May-24-23 04:05PM	Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit (GlobeNewswire)
May-13-23 08:19AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Trimmed Their Revenue Forecasts By 25% (Simply Wall St.)
May-10-23 06:10AM	Revolution Medicines First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-09-23 09:40AM	Q1 2023 Revolution Medicines Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:25PM	Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-03-23 10:00AM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:55AM	Wall Street Analysts Think Revolution Medicines, Inc. (RVMD) Could Surge 27.24%: Read This Before Placing a Bet (Zacks)
May-01-23 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023 (GlobeNewswire)
10:01AM	Revolution Medicines, Inc. (RVMD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-19-23 07:15AM	Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns climbed after last week's 16% gain, institutional investors must be happy (Simply Wall St.)
Apr-13-23 04:05PM	Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference (GlobeNewswire) +7.83%
Apr-06-23 07:00AM	Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-22-23 11:29AM	Revolution Medicines (NASDAQ:RVMD investor three-year losses grow to 18% as the stock sheds US$171m this past week (Simply Wall St.)
Mar-11-23 03:27AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 04:02PM	Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.71%
Mar-02-23 09:15PM	Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock (GlobeNewswire) -11.72% +8.78%
Mar-01-23 04:17PM	Revolution Medicines Announces Commencement of Public Offering of Common Stock (GlobeNewswire)
Feb-27-23 06:25PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +9.81%
04:05PM	Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-21-23 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023 (GlobeNewswire)
Feb-02-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Revolution Medicines, Inc. (RVMD) is a Great Choice (Zacks)
07:00AM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-23-23 05:31AM	Insiders sitting comfortably on a US$376k profit after buying Revolution Medicines, Inc. (NASDAQ:RVMD) stock worth US$1.0m last year (Simply Wall St.)
Jan-12-23 03:25AM	Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength? (Zacks) +11.12%
Jan-03-23 07:00AM	Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-22 06:15AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-26-22 08:14AM	We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely (Simply Wall St.)
Dec-19-22 07:00AM	Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor (GlobeNewswire) -9.42%
Dec-08-22 06:19AM	Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration (Benzinga)
Dec-07-22 04:05PM	Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofis Termination of SHP2 Inhibitor Development and Commercialization Collaboration (GlobeNewswire)
Nov-10-22 05:48AM	Institutional owners may consider drastic measures as Revolution Medicines, Inc.'s (NASDAQ:RVMD) recent US$110m drop adds to long-term losses (Simply Wall St.) +13.34%
Nov-09-22 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-22 05:55PM	Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-02-22 10:01AM	Alpine Immune Sciences, Inc. (ALPN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
09:54AM	Harvard University Stock Portfolio: Top 10 Picks (Insider Monkey)
Nov-01-22 04:05PM	Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022 (GlobeNewswire)
Oct-24-22 11:07AM	Who Doesnt Like a Bargain?: Oppenheimer Suggests 2 Stocks to Buy (TipRanks)
Oct-13-22 11:05AM	Loss-making Revolution Medicines (NASDAQ:RVMD) sheds a further US$68m, taking total shareholder losses to 33% over 1 year (Simply Wall St.)
Sep-22-22 07:00AM	Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Companys First Mutant-Selective RAS(ON) Inhibitor (GlobeNewswire) +5.44%
Sep-01-22 04:05PM	Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire (GlobeNewswire)
Aug-31-22 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-30-22 09:55AM	Wall Street Analysts See a 45% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High? (Zacks)
Aug-12-22 09:55AM	Wall Street Analysts Predict a 32% Upside in Revolution Medicines, Inc. (RVMD): Here's What You Should Know (Zacks) +8.21%
Aug-10-22 08:35AM	Need To Know: Analysts Are Much More Bullish On Revolution Medicines, Inc. (NASDAQ:RVMD) Revenues (Simply Wall St.)
Aug-09-22 06:15PM	Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress (GlobeNewswire)
Jul-28-22 04:02PM	Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022 (GlobeNewswire)

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kelsey Stephen Michael	See Remarks	Jul 15 '24	Option Exercise	4.09	16,667	68,168	285,740	Jul 17 04:07 PM
Kelsey Stephen Michael	See Remarks	Jul 15 '24	Sale	46.47	16,667	774,516	269,073	Jul 17 04:07 PM
GOLDSMITH MARK A	See Remarks	Jul 12 '24	Option Exercise	4.09	25,000	102,250	336,885	Jul 16 05:05 PM
GOLDSMITH MARK A	See Remarks	Jul 12 '24	Sale	45.05	25,000	1,126,205	311,885	Jul 16 05:05 PM
GOLDSMITH MARK A	See Remarks	Jul 12 '24	Sale	45.01	10,000	450,117	25,424	Jul 16 05:05 PM
Patel Sushil	Director	Jul 09 '24	Option Exercise	16.80	2,155	36,204	22,103	Jul 10 04:36 PM
Cislini Jeff	General Counsel	Jul 09 '24	Sale	40.83	2,399	97,951	47,088	Jul 10 04:36 PM
Patel Sushil	Director	Jul 09 '24	Sale	44.00	2,155	94,820	19,948	Jul 10 04:36 PM
Cislini Jeff	General Counsel	Jun 26 '24	Sale	38.47	2,000	76,940	49,487	Jun 27 06:48 PM
Kelsey Stephen Michael	See Remarks	Jun 25 '24	Option Exercise	4.09	16,467	67,350	285,540	Jun 26 04:26 PM
Kelsey Stephen Michael	See Remarks	Jun 25 '24	Sale	39.06	16,467	643,152	269,073	Jun 26 04:26 PM
Kelsey Stephen Michael	See Remarks	Jun 24 '24	Option Exercise	4.09	200	818	269,273	Jun 26 04:26 PM
Kelsey Stephen Michael	See Remarks	Jun 24 '24	Sale	39.00	200	7,800	269,073	Jun 26 04:26 PM
GOLDSMITH MARK A	See Remarks	Jun 17 '24	Sale	37.39	11,950	446,770	311,885	Jun 20 04:14 PM
Wei Lin	Chief Medical Officer	Jun 17 '24	Sale	37.39	5,589	208,954	70,851	Jun 20 04:10 PM
Horn Margaret A	Chief Operating Officer	Jun 17 '24	Sale	37.39	4,415	165,064	136,651	Jun 20 04:12 PM
Kelsey Stephen Michael	See Remarks	Jun 17 '24	Sale	37.39	3,349	125,209	269,073	Jun 20 04:11 PM
Anders Jack	Chief Financial Officer	Jun 17 '24	Sale	37.39	1,893	70,775	101,176	Jun 20 04:13 PM
Cislini Jeff	General Counsel	Jun 17 '24	Sale	37.39	1,757	65,690	51,487	Jun 20 04:11 PM
GOLDSMITH MARK A	See Remarks	Jun 03 '24	Option Exercise	4.09	7,500	30,675	329,822	Jun 05 04:18 PM
GOLDSMITH MARK A	See Remarks	Jun 03 '24	Sale	39.99	7,500	299,942	322,322	Jun 05 04:18 PM
Cislini Jeff	General Counsel	May 21 '24	Sale	39.11	1,500	58,671	52,874	May 22 04:11 PM
Anders Jack	Chief Financial Officer	May 03 '24	Option Exercise	2.68	10,000	26,800	111,959	May 03 07:36 PM
Anders Jack	Chief Financial Officer	May 03 '24	Sale	40.03	10,000	400,260	101,959	May 03 07:36 PM
Patel Sushil	Director	Apr 10 '24	Option Exercise	16.80	2,155	36,204	17,855	Apr 12 04:23 PM
GOLDSMITH MARK A	See Remarks	Apr 10 '24	Sale	35.33	10,000	353,346	30,424	Apr 12 08:08 PM
GOLDSMITH MARK A	See Remarks	Apr 10 '24	Sale	35.48	7,500	266,122	452,879	Apr 12 08:08 PM
Patel Sushil	Director	Apr 10 '24	Sale	37.00	2,155	79,735	15,700	Apr 12 04:23 PM
Cislini Jeff	General Counsel	Mar 27 '24	Sale	30.99	1,500	46,481	54,374	Mar 28 04:11 PM
GOLDSMITH MARK A	See Remarks	Mar 18 '24	Sale	31.58	5,788	182,804	460,379	Mar 20 04:44 PM
Horn Margaret A	Chief Operating Officer	Mar 18 '24	Sale	31.58	2,914	92,033	139,553	Mar 20 04:44 PM
Kelsey Stephen Michael	See Remarks	Mar 18 '24	Sale	31.58	2,123	67,051	270,909	Mar 20 04:45 PM
Anders Jack	Chief Financial Officer	Mar 18 '24	Sale	31.58	1,261	39,826	101,959	Mar 20 04:43 PM
Cislini Jeff	General Counsel	Mar 18 '24	Sale	31.58	1,252	39,542	55,874	Mar 20 04:45 PM
Horn Margaret A	Chief Operating Officer	Mar 12 '24	Option Exercise	4.09	7,936	32,458	150,403	Mar 13 04:32 PM
Horn Margaret A	Chief Operating Officer	Mar 12 '24	Sale	34.07	7,936	270,345	142,467	Mar 13 04:32 PM
Horn Margaret A	Chief Operating Officer	Mar 11 '24	Option Exercise	4.09	15,735	64,356	158,202	Mar 13 04:32 PM
Horn Margaret A	Chief Operating Officer	Mar 11 '24	Sale	34.02	15,735	535,306	142,467	Mar 13 04:32 PM
Cislini Jeff	General Counsel	Jan 22 '24	Sale	27.00	1,500	40,500	36,126	Jan 24 04:12 PM
Kelsey Stephen Michael	See Remarks	Jan 08 '24	Sale	29.01	3,337	96,809	221,632	Jan 10 04:26 PM
Kelsey Stephen Michael	See Remarks	Jan 02 '24	Sale	29.10	13,330	387,884	224,969	Jan 04 04:06 PM
Kelsey Stephen Michael	See Remarks	Dec 27 '23	Sale	29.01	33,334	966,996	238,299	Dec 29 04:14 PM
GOLDSMITH MARK A	See Remarks	Dec 18 '23	Sale	25.90	8,165	211,488	376,167	Dec 20 05:08 PM
Horn Margaret A	Chief Operating Officer	Dec 18 '23	Sale	25.90	2,993	77,524	101,467	Dec 19 07:30 PM
Kelsey Stephen Michael	See Remarks	Dec 18 '23	Sale	25.90	2,088	54,083	271,633	Dec 20 05:07 PM
Anders Jack	Chief Financial Officer	Dec 18 '23	Sale	25.90	1,775	45,976	76,416	Dec 20 05:10 PM
Cislini Jeff	General Counsel	Dec 18 '23	Sale	25.90	1,229	31,833	37,284	Dec 20 05:08 PM
Horn Margaret A	Chief Operating Officer	Dec 15 '23	Option Exercise	4.09	5,000	20,450	109,460	Dec 19 07:30 PM
Horn Margaret A	Chief Operating Officer	Dec 15 '23	Sale	26.64	5,000	133,183	104,460	Dec 19 07:30 PM
Horn Margaret A	Chief Operating Officer	Dec 06 '23	Option Exercise	4.09	5,000	20,450	109,460	Dec 08 04:08 PM
Horn Margaret A	Chief Operating Officer	Dec 06 '23	Sale	25.00	5,000	125,000	104,460	Dec 08 04:08 PM
Cislini Jeff	General Counsel	Nov 20 '23	Sale	21.70	1,500	32,545	38,513	Nov 20 06:24 PM
Horn Margaret A	Chief Operating Officer	Oct 25 '23	Option Exercise	0.54	7,500	4,050	104,460	Oct 25 06:20 PM
GOLDSMITH MARK A	See Remarks	Oct 24 '23	Option Exercise	0.49	35,000	17,150	384,332	Oct 24 07:21 PM
Anders Jack	Chief Financial Officer	Oct 23 '23	Option Exercise	2.98	24,524	72,967	78,191	Oct 23 06:01 PM
Horn Margaret A	Chief Operating Officer	Oct 16 '23	Option Exercise	4.09	25,000	102,250	121,960	Oct 18 04:23 PM
Horn Margaret A	Chief Operating Officer	Oct 16 '23	Sale	33.95	25,000	848,806	96,960	Oct 18 04:23 PM
Kelsey Stephen Michael	See Remarks	Oct 11 '23	Sale	29.05	16,667	484,130	273,721	Oct 13 04:20 PM
Cislini Jeff	General Counsel	Sep 28 '23	Sale	28.20	2,000	56,394	40,013	Oct 02 04:12 PM
GOLDSMITH MARK A	See Remarks	Sep 18 '23	Sale	31.31	8,054	252,175	349,332	Sep 20 04:12 PM
Horn Margaret A	Chief Operating Officer	Sep 18 '23	Sale	31.31	2,514	78,715	96,960	Sep 19 04:17 PM
Kelsey Stephen Michael	See Remarks	Sep 18 '23	Sale	31.31	2,060	64,500	290,388	Sep 20 04:13 PM
Anders Jack	Chief Financial Officer	Sep 18 '23	Sale	31.31	1,427	44,680	53,667	Sep 20 04:11 PM
Cislini Jeff	General Counsel	Sep 18 '23	Sale	31.31	1,214	38,011	42,013	Sep 20 04:11 PM
Horn Margaret A	Chief Operating Officer	Sep 15 '23	Option Exercise	4.09	5,000	20,450	104,474	Sep 19 04:17 PM
Horn Margaret A	Chief Operating Officer	Sep 15 '23	Sale	32.08	5,000	160,408	99,474	Sep 19 04:17 PM
Weber Barbara	Director	Sep 01 '23	Option Exercise	3.80	15,000	57,037	30,825	Sep 06 08:03 PM
Anders Jack	Chief Financial Officer	Sep 01 '23	Option Exercise	2.68	20,000	53,600	75,094	Sep 06 08:02 PM
GOLDSMITH MARK A	See Remarks	Sep 01 '23	Option Exercise	0.77	30,000	23,164	387,386	Sep 06 08:05 PM
GOLDSMITH MARK A	See Remarks	Sep 01 '23	Sale	35.05	30,000	1,051,563	357,386	Sep 06 08:05 PM
Anders Jack	Chief Financial Officer	Sep 01 '23	Sale	35.05	20,000	701,092	55,094	Sep 06 08:02 PM
Weber Barbara	Director	Sep 01 '23	Sale	35.07	15,000	526,000	15,825	Sep 06 08:03 PM
GOLDSMITH MARK A	See Remarks	Sep 01 '23	Sale	35.04	10,000	350,410	35,424	Sep 06 08:05 PM
Horn Margaret A	Chief Operating Officer	Aug 31 '23	Option Exercise	4.09	10,000	40,900	109,474	Sep 01 04:16 PM
Horn Margaret A	Chief Operating Officer	Aug 31 '23	Sale	34.05	10,000	340,458	99,474	Sep 01 04:16 PM
Horn Margaret A	Chief Operating Officer	Aug 15 '23	Option Exercise	4.09	5,000	20,450	104,474	Aug 17 04:17 PM
Horn Margaret A	Chief Operating Officer	Aug 15 '23	Sale	30.53	5,000	152,632	99,474	Aug 17 04:17 PM
Kelsey Stephen Michael	See Remarks	Aug 02 '23	Sale	32.40	16,666	539,978	292,448	Aug 03 04:17 PM
Kelsey Stephen Michael	See Remarks	Aug 01 '23	Sale	29.19	16,666	486,502	309,114	Aug 03 04:17 PM
Cislini Jeff	General Counsel	Jul 31 '23	Sale	26.02	1,500	39,030	43,227	Aug 01 06:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RVMD

Revolution Medicines Inc

Upgrade your FINVIZ experience